Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies

BACKGROUND: Oncolytic viral tumor therapy is an emerging field in the fight against cancer with rising numbers of clinical trials and the first clinically approved product (Adenovirus for the treatment of Head and Neck Cancer in China) in this field. Yet, until recently no general (bio)marker or rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Hess, Michael, Stritzker, Jochen, Härtl, Barbara, Sturm, Julia B, Gentschev, Ivaylo, Szalay, Aladar A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207905/
https://www.ncbi.nlm.nih.gov/pubmed/21989091
http://dx.doi.org/10.1186/1479-5876-9-172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207905/
https://www.ncbi.nlm.nih.gov/pubmed/21989091
http://dx.doi.org/10.1186/1479-5876-9-172

Ejemplares similares